What is William Blair’s Forecast for uniQure Q1 Earnings?

uniQure (NASDAQ:QURE) – Analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of uniQure in a research note issued on Thursday, February 27th. William Blair analyst S. Corwin expects that the biotechnology company will post earnings per share of ($1.39) for the quarter. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. William Blair also issued estimates for uniQure’s Q2 2026 earnings at ($1.41) EPS, Q3 2026 earnings at ($1.27) EPS and Q4 2026 earnings at ($1.22) EPS.

A number of other research firms have also recently weighed in on QURE. Cantor Fitzgerald boosted their price objective on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, December 10th. Leerink Partners lifted their price target on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. Finally, The Goldman Sachs Group lifted their price target on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

uniQure Stock Performance

NASDAQ:QURE opened at $12.07 on Friday. The firm has a market capitalization of $588.33 million, a PE ratio of -2.43 and a beta of 0.38. The stock’s fifty day moving average is $15.12 and its 200 day moving average is $9.75. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $19.18. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

Insider Buying and Selling at uniQure

In other news, CEO Matthew C. Kapusta sold 26,727 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total value of $285,978.90. Following the completion of the sale, the chief executive officer now owns 571,188 shares in the company, valued at approximately $6,111,711.60. The trade was a 4.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Christian Klemt sold 14,341 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the completion of the sale, the chief financial officer now owns 152,372 shares of the company’s stock, valued at approximately $1,630,380.40. This represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 55,915 shares of company stock valued at $588,112 in the last three months. Company insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

Several large investors have recently modified their holdings of the business. Twin Tree Management LP bought a new position in shares of uniQure during the 4th quarter worth approximately $77,000. FNY Investment Advisers LLC bought a new position in shares of uniQure during the 4th quarter worth approximately $88,000. RTW Investments LP bought a new position in shares of uniQure during the 3rd quarter worth approximately $49,000. ADAR1 Capital Management LLC bought a new position in shares of uniQure during the 4th quarter worth approximately $177,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 3,663 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.